Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revlimid Multiple Myeloma Trial Paused Due to Blood Clots

This article was originally published in The Pink Sheet Daily

Executive Summary

Celgene asserts that the Mayo Clinic study will resume within weeks, after the trial design is changed to require patients to receive aspirin prior to combo therapy of Revlimid/dexamethasone.

You may also be interested in...



Celgene’s Revlimid In Multiple Myeloma Reviewed At ASCO For Risk Of Thrombosis

Study finds that concurrent use of erythropoietin agents with Revlimid and dexamethasone should be minimized.

Celgene’s Revlimid In Multiple Myeloma Reviewed At ASCO For Risk Of Thrombosis

Study finds that concurrent use of erythropoietin agents with Revlimid and dexamethasone should be minimized.

Revlimid Approved With Safeguards Against Fetal Exposure

Education and prescribing safety program for Celgene’s Revlimid will restrict distribution and address risks of fetal exposure; the firm has ongoing studies to assess teratogenicity.

Related Content

Topics

UsernamePublicRestriction

Register

PS062966

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel